Bibliography
- Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad Child Adolesc Psychiatry 1995;34:454-63
- Costello EJ, Angold A, Burns BJ, et al. The Great Smoky Mountains Study of Youth: goals, design, methods and the prevalence of DSM-III-R disorders. Arch Gen Psychiatry 1996;53:1129-36
- Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1997;36:1168-76
- DelBello MP, Hanseman D, Adler CM, et al. Twelve-month outcomes of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry 2007;164:582-90
- Geller B, Tillman R, Craney JL, Bolhofner K. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch Gen Psychiatry 2004;61:459-67
- Perlis RH, Miyahara S, Marangell LB, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2004;55:875-81
- Carter TD, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res 2003;37:297-303
- Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006;63:1139-48
- Pfeifer JC, Kowatch RA, DelBello MP. The use of antipsychotics in children and adolescents with bipolar disorders. Expert Opin Pharmacother 2007;8:2673-87
- DelBello MP, Kowatch RA. Pharmacological interventions for bipolar youth: developmental considerations. Dev Psychopathol 2006;18:1231-46
- Bhangoo RK, Lowe CH, Myers FS, et al. Medication use in children and adolescents treated in the community for bipolar disorder. J Child Adolesc Psychopharmacol 2003;13:515-22
- Miklowitz DJ. The role of family systems in severe and recurrent psychiatric disorders: a developmental psychopathology view. Dev Psychopathol 2004;16:667-88
- Lewinsohn PM, Seeley JR, Buckley ME, Klein DN. Bipolar disorder in adolescence and young adulthood. Child Adolesc Psychiatr Clin N Am 2002;11:461-75
- Olfson M, Blanco C, Liu L, et al. National trends in outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679-85
- Eli Lilly and Company. Package Insert; 2006
- Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33:298-304
- Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-8
- Mauri MD, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationships between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-88
- Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood onset schizophrenia. J Clin Psychopharmacol 2000;20:220-5
- Theisen FM, Haberhausen M, Schulz E, et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 2006;28:750-9
- Aichorn W, Marksteiner J, Walch T, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol 2007;17:665-74
- Eli Lilly and Company. Pharmacokinetic data on file; 2007
- DelBello MP, Cecil KM, Adler CM, et al. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2006;31:1264-73
- Biederman J, Mick E, Hammerness P, et al. Open-label, 8 week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005;58:589-94
- Frazier JA, Biederman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001;11:239-50
- Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007;146:1547-56
- Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-35
- Khan SS, Mican LM. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J Child Adolesc Psychopharmacol 2006;16:671-7
- Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-56
- Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-90
- Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-26
- Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-7
- Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-9
- Patel NC, Kistler JS, James EB, Crismon ML. A retrospective analysis of short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 2004;24:824-30
- Kwon JS, Choi JS, Bahk WM, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 2006;67:547-53
- Alvarez-Jimenez M, Gonzalez-Blanch, Vazquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naïve first episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006;67:1253-60
- Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072-9
- Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olazapine treatment. Eur Neuropsychopharmacol 2005;15:13-21
- Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954-62
- Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-7
- Strawn JR, Adler CM, Strakowski SM, DelBello MP. Hyperthermia and rhabdomyolysis in an adolescent treated with olanzapine and topiramate. J Child Adolesc Psychopharmacol 2008; In Press
- Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998;37:377-85
- Alfaro CL, Wudarsky M, Nicholson R, et al. Correlation of antipsychotic and prolactin concentration in children and adolescents acutelty treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 2002;12:83-91
- Woods SW, Martin A, Spector SG, McGlashan TH. Effect of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002;41:1439-46
- Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29:133-45
- Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:359-71
- Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007;93:136-43
- Becker AL, Epperson CN. Female puberty: clinical implications for the use of prolactin-modulating psychotropics. Chil Adolesc Psychiatric Clin N Am 2006;15:207-20
- Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 2004;14:350-8
- Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-314
- Cavestro C, Rosatello A, Marino MP, et al. High prolactin levels as a worsening factor for migraine. J Headache Pain 2006;7:83-9
- Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007;25:1482-8
- Pogge DL, Singer MB, Harvey PD. Rates and predictors of adherence with atypical antipsychotic medications: a follow-up study of adolescent inpatients. J Child Adolesc Psychopharmacol 2005;15:901-12